Formula I Compounds for Hepatitis C Viral Elimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infection are limited by the lack of effective vaccines and therapies, with genotype 1 being particularly difficult to treat and existing treatments having poor efficacy and severe side effects.
Innovation Solution
Development of novel compounds of formula I, which are effective against HCV, including pharmaceutically acceptable salts, that target specific mechanisms of action, inhibition efficacy, and safety profiles, potentially used in combination with other antiviral agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pegylated alpha-interferon and ribavirin combination therapy is used to treat HCV, then viral elimination is achieved for approximately 50% of genotype 1 patients, but severe side effects occur and treatment response is poor
Solution Approach 1:
The patent applies parameter changes by developing compounds with modified chemical structures (formula I with various substituents R1-R7) that alter the pharmacological properties compared to existing interferon and ribavirin therapies. This structural modification aims to achieve comparable or improved antiviral efficacy while reducing the severe side effects associated with conventional treatment parameters
Solution Approach 2:
The patent employs composite materials by creating complex molecular structures that combine multiple functional groups and substituents in a single compound framework. These composite chemical structures are designed to achieve multi-target antiviral activity against HCV while improving the safety profile compared to simple monotherapies
2Reliability
If genotype 1 HCV is treated with current therapies, then some viral elimination is achieved, but treatment difficulty remains high with only 50% sustained virologic response
Solution Approach 1:
The patent extracts the essential antiviral activity from complex combination therapies by developing single compounds (formula I) that can target multiple viral mechanisms simultaneously. This extraction approach simplifies the treatment regimen while maintaining or improving efficacy against difficult-to-treat genotype 1 HCV
Solution Approach 2:
The patent applies universality by designing compounds with multiple substituents and functional groups that enable a single agent to perform multiple antiviral functions. These multi-functional compounds aim to address various stages of the HCV lifecycle, providing broad-spectrum activity against genotype 1 and potentially other genotypes
Data Source
AI summary
The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.